Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034606 · ClinicalTrials.gov registry record · Phase 2
Comparing 3 Schedules of Alimta Plus Gemzar
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00034606: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00034606 is a Phase 2 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034606, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.
Interventions
- DRUG Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00034606 record still lists
NCT00034606 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed (Alimta) in combination with gemcitabine (Gemzar) is the first listed.
NCT00034606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00034606 about?
NCT00034606 is a clinical study titled "Comparing 3 Schedules of Alimta Plus Gemzar". The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.
What is the current status of trial NCT00034606?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00034606?
The interventions under investigation include: Pemetrexed (Alimta) in combination with gemcitabine (Gemzar) (DRUG).
Who is sponsoring clinical trial NCT00034606?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.